Valneva SE
(XTER:AYJ)
€
3.142
-0.018 (-0.57%)
Market Cap: 431.93 Mil
Enterprise Value: 466.96 Mil
PE Ratio: 0
PB Ratio: 2.28
GF Score: 75/100 - Q1 2024 Valneva SE Earnings Call TranscriptMay 07, 2024€3.41 (-1.16%)Earnings
- Full Year 2023 Valneva SE Earnings Call TranscriptMar 20, 2024€3.37 (-10.66%)Earnings
- Valneva SE Analyst Call TranscriptNov 13, 2023
- Q3 2023 Valneva SE Earnings Call TranscriptNov 09, 2023€6.18 (+0.62%)Earnings
- Half Year 2023 Valneva SE Earnings Call TranscriptSep 21, 2023€6.04 (-4.16%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 07, 2023
- Q1 2023 Valneva SE Earnings Call TranscriptMay 04, 2023€5.31 (+26.70%)Earnings
- Full Year 2022 Valneva SE Earnings Call TranscriptMar 23, 2023€4.82 (-1.63%)Earnings
- Valneva SE Corporate Analyst Meeting TranscriptDec 06, 2022
- Q3 2022 Valneva SE Earnings Call TranscriptNov 10, 2022€7 (+4.60%)Earnings
- Half Year 2022 Valneva SE Earnings Call TranscriptAug 11, 2022€9.96 (-5.14%)Earnings
- Valneva SE at Jefferies Healthcare Conference TranscriptJun 09, 2022
- Valneva SE COVID-19 Vaccine Purchase Agreement Update TranscriptMay 16, 2022
- Q1 2022 Valneva SE Earnings Call TranscriptMay 05, 2022€11.86 (+0.13%)Earnings
- Full Year 2021 Valneva SE Earnings Call TranscriptMar 24, 2022€17.35 (+1.17%)Earnings
- Valneva SE - Special Call TranscriptOct 18, 2021
- Half Year 2021 Valneva SE Earnings Call TranscriptAug 10, 2021€3.1Earnings
- Valneva SE Annual Shareholders Meeting TranscriptJun 23, 2021
- Q1 2021 Valneva SE Earnings Call TranscriptMay 20, 2021€3.1Earnings
- Full Year 2020 Valneva SE Earnings Call TranscriptFeb 25, 2021€3.1Earnings
- Q3 2020 Valneva SE Earnings Call TranscriptNov 03, 2020€3.1Earnings
- Half Year 2020 Valneva SE Earnings Call TranscriptAug 04, 2020€3.1Earnings
- Q1 2020 Valneva SE Earnings Call TranscriptMay 07, 2020€3.1Earnings
- Full Year 2019 Valneva SE Earnings Call TranscriptFeb 27, 2020€3.1Earnings
- Nine Months 2019 Valneva SE Earnings Call TranscriptOct 31, 2019€3.1Earnings
- Half Year 2019 Valneva SE Earnings Call TranscriptAug 01, 2019€3.1Earnings
- Valneva SE R&D Investor Day Presentation TranscriptJul 09, 2019
- Valneva SE to Announce Agreement with GlaxoSmithKline PLC to End Strategic Alliance Agreement Call TranscriptJun 21, 2019
- Q1 2019 Valneva SE Earnings Call TranscriptMay 02, 2019€3.1Earnings
- Full Year 2018 Valneva SE Earnings Call TranscriptFeb 21, 2019€3.1Earnings
Valneva SE at Jefferies Healthcare Conference Transcript
Jun 09, 2022 / 03:30PM GMT
Release Date Price:
€11.38
(-2.94%)
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome the CEO of Valneva, Thomas Lingelbach. Thanks for joining us today, Thomas.
Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO
Pleasure. Thank you.
Maurice Thomas Raycroft
Jefferies LLC, Research Division - Equity Analyst
And we're going to do a fireside chat format. So maybe to start off, for those who are new to the story, if you can provide a 1-minute intro highlighting your main products and key catalysts ahead.
Thomas Lingelbach
Valneva SE - Chairman of the Management Board, President & CEO
Yes. So Valneva is a specialty vaccine company, focusing on the commercialization and development of vaccines in areas of high unmet medical need. We have commercial products in the field of travel vaccines. And we have 3 major advanced clinical stage assets, all of them
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)